Innovative symbiotic transcatheter pacemaker harvests heart motion energy for lifelong pacing. Learn how this could transform ...

Cardiac device therapy has significantly evolved since the introduction of the first implantable pacemaker and the subsequent ...

Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of ...

PURCHASE, N.Y., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), today announced that a manuscript entitled, “Phase 2 Study of Zervimesine (CT1812) in Participants with ...

Foresee Pharmaceuticals has shown that a long-acting version of its injectable prostate cancer med Camcevi can help patients with central precocious puberty (CPP), potentially opening the door to a ...

Two major trials investigating the potential of the psychedelic drug LSD for reducing anxiety are set to conclude in 2026. Scientists are feeling positive after the drug’s success in an earlier-stage ...

The biggest stories of the day delivered to your inbox.

Arcus Biosciences and Gilead Sciences are discontinuing a Phase 3 trial of an experimental cancer treatment after an interim review showed the therapy was unlikely to help patients live longer. Arcus ...

In a nutshell, the company's suite of software solutions helps its customers work smarter. Its core end-market customers are mainly manufacturing companies, and its key selling point is enabling them ...

Despite Shell’s exit from the first phase, it may consider involvement in expansion phases. Regardless, development plans for Phase 1 remain unchanged with plans for two FLNG units with combined ...

Ianalumab combined with eltrombopag significantly extends time to treatment failure and improves stable response rates in ITP patients relapsing after first-line steroids. The combination therapy ...

Kymera Therapeutics, Inc. reported robust Phase 1b results for KT-621, showing deep STAT6 degradation and strong clinical efficacy in atopic dermatitis. KT-621 demonstrated a favorable safety profile, ...